Shares of Citius Pharmaceuticals (NASDAQ: CTXR) , a clinical-stage biopharmaceutical company, are getting beaten down today after the company released disappointing news regarding its lead candidate, Mino-Lok. Investors, worried that the treatment isn't going anywhere fast, dragged the stock 19.8% lower as of 12:10 p.m. EDT on Thursday.
Throughout most of June, Citius Pharmaceuticals stock climbed in anticipation of the third planned interim analysis of a phase 3 trial with Mino-Lok. This is an antibiotic lock solution that could be used to salvage central line catheters that become infected.
Image source: Getty Images.
For further details see:
Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today